The use of anticoagulants: patient experiences, adherence and societal costs.

Since 2009, the New Oral Anti-Coagulation (NOACs) are on the market. This treatment considerably differs from its predecessors (VKAs).
The aim is to measure patient experiences and its association with adherence, costs of care (eg by decreasing the use of care) and social costs.
1 Patient experiences with oral anticoagulation and its association with adherence, health care utilization and absenteeism are measured using a structured questionnaire: the Tailored Medication Inventory anticoagulation
2. The insertion of adherence and potential related impact on effectiveness and efficiency in a cost model previously developed for NOACs
Insight is gained in how NOACs are used and how patients experience these medicines. There will also be insight into how these experiences affect costs. The latter is important for: 1) determining the reimbursement; 2) determining the position of the NOACs in professional guidelines and3) to support individual health care providers in their pharmaceutical care.
Bristol Myer-Squibb
In this project we work together with
Rijksuniversiteit Groningen (prof. dr. Maarten Postma)